Value20202021202220232024TTMSelling/general/admin expenses199.62 M184.99 M109.08 M142.52 M163.07 M161.28 MResearch & development159.44 M105.97 M118.93 M86.11 M46.24 M44.9 MOperating income121.4 M226.73 M179.5 M155.56 M54.4 M2.68 MNon-Operating Income, Total515 K3.98 M2.65 M5.29 M8.02 M3.62 MInterest expense, net of interest capitalized22.67 M46.35 M56.81 M58.98 M59.25 M78.39 MNon-Operating Income, excl. Interest Expenses-22.67 M-46.35 M-56.81 M-58.98 M-59.25 M-78.39 MUnusual income/expense515 K3.98 M2.65 M5.29 M8.02 M3.62 MPretax income121.91 M233.35 M182.15 M160.85 M58.09 M-72.09 MEquity in earnings——————Taxes000000Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations143.55 M269.11 M233.66 M209.25 M51.74 M-16.21 MDiscontinued operations——————Net income143.55 M269.11 M233.66 M209.25 M51.74 M-16.21 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders143.55 M269.11 M233.66 M209.25 M51.74 M-16.21 MBasic earnings per share (Basic EPS)—-9.31-3.52-2.03-0.28-0.59Diluted earnings per share (Diluted EPS)—-9.31-3.52-2.03-0.28-0.57Average basic shares outstanding—28.9 M66.41 M103.11 M187.18 M781.59 MDiluted shares outstanding—28.9 M66.41 M103.11 M187.18 M781.59 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)2.14 M2.21 M1.84 M1.49 M1.6 M2.68 M
Esperion Therapeutics Inc
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.